# Clinical Trials Data BRAF - Document 7

# A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

## Clinical Trial: https://clinicaltrials.gov/study/NCT01449058

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologically/cytologically confirmed, advanced solid tumors, AML or high risk and very high risk MDS\n\* Measurable disease as determined by RECIST 1.1\n\nExclusion Criteria:\n\n\* Primary CNS tumor or CNS tumor involvement\n\* Diabetes mellitus\n\* Unacceptable ocular/retinal conditions\n\* Clinically significant cardiac disease or impaired cardiac function",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
The provided eligibility criteria for the clinical trial do not specify any exclusion based on BRAF gene mutations. Therefore, based on the given information alone, a patient with a BRAF gene mutation would not be automatically excluded from this trial and may be eligible. However, it is important to note that this determination does not consider any other possible criteria that might not be listed here or any specific considerations that might apply to the study's goals or the investigational drug's mechanism. It's always advisable to consult with the trial coordinator or a healthcare provider for confirmation of eligibility.